Stonepine Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.85M | Buy |
225,000
+131,607
| +141% | +$2.84M | 4.76% | 6 |
|
|
2025
Q1 | $186K | Sell |
93,393
-126,607
| -58% | -$252K | 0.18% | 51 |
|
|
2024
Q4 | $4.04M | Buy |
220,000
+23,105
| +12% | +$424K | 3.26% | 7 |
|
|
2024
Q3 | $3.03M | Buy |
196,895
+191,895
| +3,838% | +$2.95M | 1.91% | 17 |
|
|
2024
Q2 | $81.3K | Buy |
+5,000
| New | +$81.3K | 0.07% | 25 |
|
|
2018
Q3 | – | Sell |
-194,900
| Closed | -$2.98M | – | 32 |
|
|
2018
Q2 | $2.98M | Buy |
+194,900
| New | +$2.98M | 1.81% | 16 |
|